louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04780906: Influence of Wrist Taping on Handgrip Strength in Crossfit Athletes
Official title: Influence of Wrist Taping on Handgrip Strength in Crossfit Athletes - Crossover Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sport Injury
Hand Injury Wrist
Keywords: sports
Lead sponsor: Vita Care
Sponsor class: OTHER
First posted: 2021-03-04
Enrollment: 54
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The idea that the use of a wristband can increase the grip strength is old, but without systematic scientific evidence. Most Crossfit practitioners wear wrist bands during training because it is believed that the wristband increases the grip strength of the hand. The aim of this study is to to analyze the influence of the use of the wristband on the maximum force value and on the dynamic resistance of hand hold. A simple blind randomized cross-over trial will be performed.


Eligibility criteria: Inclusion Criteria:

* be an amateur practitioner of the Crossfit modality with at least 6 months of regular sports practice (at least 4 times a week)
* between 18-40 years old
* agree to participate in the study and sign the informed consent form (ICF).

Exclusion Criteria:

* active wrist/ arm injury or pain on the day of the test (pain score greater than 3 in 10 for both shoulder, forearm, wrist and / or hand on the VAS pain scale)
* history of wrist injury (especially fracture or ligament injury)
* previous wrist surgery

Primary outcomes:
measure: Grip
timeFrame: 0 minutes; 5 minutes
Secondary outcomes:
measure: Endurance
timeFrame: 0 minutes; 5 minutes
Other outcomes:
Locations:
city: Sao Paulo
country: Brazil
facility: Instituto Vita
state: SP
Study officials:
affiliation: Instituto Vita
name: Luis Marchi, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT03511859: Detecting Circulating Tumor Cells (CTCs) and Cell Free DNA (cfDNA) in Peripheral Blood of Breast Cancer (BC) Patients to Develop the Clinical Application for Early Detection and Diagnostics
Official title: Detecting Circulating Tumor Cells (CTCs) and Cell Free DNA (cfDNA) in Peripheral Blood of Breast Cancer (BC) Patients to Develop the Clinical Application for Early Detection and Diagnostics
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Breast Cancer
Keywords: Breast cancer. Circulating tumor cells. CTCs. Cell free DNA. cfDNA
Lead sponsor: CellMaxLife
Sponsor class: INDUSTRY
First posted: 2018-04-30
Enrollment: 210
Sex: FEMALE
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Breast cancer patients

Brief summary: Utilization of circulating-tumor-cell (CTC) and cell free DNA (cfDNA) as novel and noninvasive tests for diagnosis confirmation, therapy selection, and cancer surveillance is a rapidly growing area of interest. In the wake of FDA approval of a liquid biopsy test, it is important for clinicians to acknowledge the obvious clinical utility of liquid biopsy for cancer management throughout the course of the disease.


Eligibility criteria: Inclusion Criteria:

* All subjects need to sign the informed consent form and age is above 20.
* Control group need to have mammogram /ultrasound results category1-3 and confirmed by PI.
* Cancer group subjects with pathology report confirmed to be malignant have not yet done surgery or treatment will be enrolled to the malignant group for analysis

Exclusion Criteria:

* Not willing to sign the informed consent form
* Have been undergone general anesthesia or regional anesthesia in 1 month
* Have been diagnosed with any type of cancer and been treated
* Have been suffering from autoimmune disorder such as SLE and RA
* Have been suffering from chronic infection such as IBD, pancreatitis, COPD or Interstitial pneumonia.
* Have been suffering from acute infection or other infectious diseases in 3 moths such as TB, pneumonia, urinary tract infection, or cellular infection
* Diagnosed with myelodysplastic syndrome or myeloproliferative diseases
* Other condition which may affect the CTC results, when determined by PI can be confirmed by other tests are if necessary

Primary outcomes:
measure: The objective of this study is to demonstrate that CTC assay counts can distinguish between healthy subjects and malignant breast cancer subjects, including early stage breast cancer subjects.
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Kaohsiung
country: Taiwan
facility: Kaohsiung Medical University Hospital
Study officials:
References:
Clinical trial NCT01335659: Main Branch Versus Side Branch Ostial Lesion
Official title: Relationship Between Fractional Flow Reserve and Coronary Angiography/Intravascular Ultrasound Parameters in Ostial Lesions: Major Coronary Ostial Lesions Versus Side Branch Ostial Lesions
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Coronary Artery Stenosis
Keywords: FFR
IVUS
QCA
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2011-04-14
Enrollment: 77
Sex: ALL
Minimum age (years): 21
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: from september 2009 to january 2011 patient who are undergone coronary angiography,IVUS and FFR for the evaluation of coronary artery disease at SNUH

Brief summary: The investigators studied the relations between coronary angiography (CAG), intravascular ultrasound (IVUS) and fractional flow reserve (FFR) in coronary ostial lesions.

Detailed description: Angiographic evaluation for ostial lesions is reported to be inaccurate in the assessment of the functional and clinical significance of a lesion. The investigators studied the relations between coronary angiography (CAG), intravascular ultrasound (IVUS) and fractional flow reserve (FFR) in coronary ostial lesions.

Eligibility criteria: Inclusion Criteria:

* Age 21-85
* Presence of at least one obstructive coronary artery stenosis at coronary ostium as defined by:
* Previous catheterization with any coronary ostium lesion 50% or greater
* Ability and Willingness to provide informed consent
* Ability and Willingness to perform required follow up procedures

Exclusion Criteria:

* History of coronary artery bypass graft surgery
* left main coronary ostial lesion
* significant stenosis at proximal or distal part of coronary ostium lesion
* ostial lesion related to infarcton
* Creatinine\>1.6 mg/dL or GFR\<30 pre-procedure per institutional standards
* Ejection fraction lower than 40%
* Known Pregnancy
* Arrhythmia
* Contrast agent allergy that cannot be adequately premedicated
* Patient not a candidate for IVUS and FFR
* Inability or unwillingness to provide informed consent
* Inability or unwillingness to perform required follow up procedures

Primary outcomes:
measure: lumen area
timeFrame: 1 day
Secondary outcomes:
measure: angiographic stenosis, % plaque area
timeFrame: 1 day
Other outcomes:
Locations:
Study officials:
affiliation: Seoul National University Hospital
name: Bon-kwon Koo, MD/PhD
role: STUDY_DIRECTOR
References:
citation: Koh JS, Koo BK, Kim JH, Yang HM, Park KW, Kang HJ, Kim HS, Oh BH, Park YB. Relationship between fractional flow reserve and angiographic and intravascular ultrasound parameters in ostial lesions: major epicardial vessel versus side branch ostial lesions. JACC Cardiovasc Interv. 2012 Apr;5(4):409-15. doi: 10.1016/j.jcin.2012.01.013.
Clinical trial NCT00904059: Drug-Drug Interaction Study in Healthy Subjects
Official title: Open-Label, Randomized, Multiple-Dose, Drug-Drug Interaction Study to Assess the Pharmacokinetics and Safety of BMS-790052 and BMS-650032 Co-administered in Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Hepatitis C
Lead sponsor: Bristol-Myers Squibb
Sponsor class: INDUSTRY
First posted: 2009-05-19
Enrollment: 28
Sex: ALL
Minimum age (years): 18
Maximum age (years): 49
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER

Brief summary: The purpose of this study is to assess the pharmacokinetics and safety of BMS-790052 and BMS-650032 when co-administered and when administered alone

Detailed description: Pharmacokinetics and Safety in Healthy Subjects

Eligibility criteria: Inclusion Criteria:

* Healthy male and female subjects aged 18 to 49 years
* Females who are not of childbearing potential, pregnant or breastfeeding
* Subject Body Mass Index (BMI) of 18 to 32 kg/m²

Exclusion Criteria:

* Women of child bearing potential
* Male subjects who have sex with women who are unwilling to agree to practice male barrier contraception during study participation and for a least 12 weeks following dosing
* Any significant acute or chronic medical illness
* Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations
* Prior exposure to BMS-650032 or BMS-790052
* Positive for HIV or HCV

Primary outcomes:
measure: Pharmacokinetic parameters including AUC (TAU) Cmax and Cmin
timeFrame: Day 21 pharmacokinetic assessment
Secondary outcomes:
measure: To assess the safety, tolerability, and fractional excretion of sodium when BMS-709952 and BMS-650032 are co-administered
timeFrame: Within 24 hours post dose
Other outcomes:
Locations:
city: Austin
country: United States
facility: Ppd Development, Lp
state: Texas
Study officials:
affiliation: Bristol-Myers Squibb
name: Bristol-Myers Squibb
role: STUDY_DIRECTOR
References:
Clinical trial NCT00082459: Trial to Compare the Routes of Administration of an Investigational, Personalized, Therapeutic Cancer Vaccine Oncophage (HSPPC-96) in Patients With Metastatic Renal Cell Carcinoma
Official title: A Randomized Phase II Study Investigating the Route of Administration of Oncophage (HSPPC-96) in Patients With Metastatic Renal Cell Carcinoma
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Renal Cell Carcinoma
Keywords: Kidney Cancer
Renal
Tumor
Immunotherapy
Lead sponsor: Agenus Inc.
Sponsor class: INDUSTRY
First posted: 2004-05-12
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The goal of this trial is to determine the safety of HSPPC-96 and which route of administration achieves a better response with the vaccine. HSPPC-96 is an immunotherapeutic agent made from an individual patient's tumor.

Detailed description: The goal of this trial is to determine the safety of HSPPC-96 and which route of administration achieves a better response with the vaccine. HSPPC-96 is an immunotherapeutic agent made from an individual patient's tumor. The study is being conducted in Houston, Texas with patients enrolled into one of two treatment arms. The two treatment arms are either subcutaneous injection or intradermal injection, both with HSPPC-96. To be treated with HSPPC-96 patients must undergo surgery to remove the kidney tumor and a portion of this tissue will be sent to Antigenics' manufacturing facility for processing.

Eligibility criteria: Inclusion Criteria:

* Suspected metastatic renal cell carcinoma (AJCC Stage IV) with intact primary tumor
* No previous therapy for metastatic renal cell carcinoma
* Measurable disease (RECIST criteria)
* Primary tumor greater than or equal to 7cm on CT or MRI
* ECOG performance status 0-1
* At least 18 years old
* Life expectancy \> 3 months
* Adequate cardiac function (NYHA I-II)
* Not pregnant
* Provide written informed consent
* Absence of multiple liver metastases, brain or threatening bone metastases (axial skeleton and/or pathological features)
* Planned complete nephrectomy

Exclusion Criteria:

* History of primary or secondary immunodeficiency, or patients using systemic corticosteroids or cyclosporin A
* Other cancer (including renal cell carcinoma) within the last five years (with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri or basal or squamous cell carcinoma of the skin)
* Embolization of the renal artery prior to nephrectomy
* Active, uncontrolled infection or other serious medical illnesses, preventing study completion, in the opinion of the Principal Investigator

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Houston
country: United States
state: Texas
Study officials:
References:
Clinical trial NCT06524700: Pectopexy Autologous Vs Mesh
Official title: Pectopexy Autologous Vs Mesh
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Uterine Prolapse
Vault Prolapse, Vaginal
Keywords: vault
uterine
prolapse
Lead sponsor: Ain Shams Maternity Hospital
Sponsor class: OTHER
Collaborators: name: Armed forces hospital wadi aldwaser
First posted: 2024-07-29
Enrollment: 20
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: prospective comparative study describing using autologous graft for uterine- vault - cervical suspension vs mesh in treatment of apical prolapse


Eligibility criteria: Inclusion Criteria:

uterine - vault prolapse

-

Exclusion Criteria:

* previous vaginal repair for uterine or vaginal prolapse previous suspension procedures for apical prolapse

Primary outcomes:
measure: POP-Q
timeFrame: 3 month
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Urogynecology Unit
city: Riyadh
country: Saudi Arabia
facility: Armed forces Hospital Wadi Aldwaser
state: Wadi Aldwaser
Study officials:
affiliation: UROGYNECOLOGY UNIT
name: Hamdy Saaid
role: STUDY_CHAIR
References:
Clinical trial NCT00851500: A Trial of the Safety and Efficacy of K-604 for the Treatment of Atherosclerosis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Atherosclerosis
Keywords: atherosclerosis
carotid artery disease
Lead sponsor: Kowa Research Institute, Inc.
Sponsor class: INDUSTRY
First posted: 2009-02-26
Enrollment: 210
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the safety and efficacy of K-604 for the treatment of atherosclerosis.


Eligibility criteria: Inclusion Criteria:

* moderate carotid artery stenosis

Exclusion Criteria:

* history of arteritis
* heavily calcified plaque
* uncontrolled hypertension
* poorly controlled diabetes
* hypercholesterolemia

Primary outcomes:
measure: Change from baseline in plaque composition over 6 months
timeFrame: 6 months
Secondary outcomes:
measure: Change from baseline in plaque size over 6 months.
timeFrame: 6 months
Other outcomes:
Locations:
city: Chandler
country: United States
state: Arizona
city: Litchfield Park
country: United States
state: Arizona
city: Phoenix
country: United States
state: Arizona
city: Los Angeles
country: United States
state: California
city: San Diego
country: United States
state: California
city: Clearwater
country: United States
state: Florida
city: Jacksonville
country: United States
state: Florida
city: St. Louis
country: United States
state: Missouri
city: Buffalo
country: United States
state: New York
city: Oklahoma City
country: United States
state: Oklahoma
city: Carrollton
country: United States
state: Texas
city: Dallas
country: United States
state: Texas
city: Houston
country: United States
state: Texas
city: Plano
country: United States
state: Texas
city: Norfolk
country: United States
state: Virginia
city: Virginia Beach
country: United States
state: Virginia
city: Olympia
country: United States
state: Washington
city: Renton
country: United States
state: Washington
city: Seattle
country: United States
state: Washington
Study officials:
References:
Clinical trial NCT04395300: Sleep Quality in Healthcare Personnel During COVID-19
Official title: Sleep Quality and Effect on General Health in Healthcare Personnel During COVID-19 Pandemic
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: COVID-19
Sleep Quality
General Health
Keywords: COVID-19
corona virus disease
Pittsburgh sleep quality index
General health questionnare
Healthcare worker
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2020-05-20
Enrollment: 143
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: physicians, nurses, laboratory and radiology technicians

Brief summary: Coronavirus disease 2019 (COVID-19), represents a medical and psychological challenge to healthcare workers to the limits that it affects their quality of sleep and their general health.


Eligibility criteria: Inclusion Criteria:

* All healthcare personnel actively working during the pandemic

Exclusion Criteria:

* non healthcare workers

Primary outcomes:
measure: measure sleep quality in healthcare worker
timeFrame: one month
Secondary outcomes:
measure: impact of covid-19 pandemic on general health
timeFrame: 40 days
measure: correlate between sleep quality and general health
timeFrame: 40 days
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: AssiutU
Study officials:
References:
Clinical trial NCT04738500: Postoperative Analgesic Efficacy of Pericapsular Nerve Group Block (PENG) Block for Knee Arthroscopy
Official title: Postoperative Analgesic Efficacy of Pericapsular Nerve Group Block (PENG) Block for Knee Arthroscopy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Postoperative Pain
Lead sponsor: Kahramanmaras Sutcu Imam University
Sponsor class: OTHER
First posted: 2021-02-04
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Pericapsular nerve group block (PENG) has been deemed as a safe and effective regional technique for postoperative pain after knee arthroscopy.

Detailed description: Pericapsular nerve group block(PENG) has been deemed as a safe and effective regional technique for postoperative pain after knee artroscopy. Blockade of the branches of the femoral and obturator nerves that provide innervation to any structures distal enough to be useful in knee.

Eligibility criteria: Inclusion Criteria:

* Patients agreed to receive PENG block
* Knee arthroscopy

Exclusion Criteria:

* Other kinds of knee surgery
* Patients refuse to receive PENG block

Primary outcomes:
measure: First analgesic demand
timeFrame: 24 Hours
Secondary outcomes:
measure: Opioid consumption
timeFrame: 24 Hours
measure: Numeric Rating Scale
timeFrame: 24 Hours
Other outcomes:
Locations:
city: Kahramanmaraş
country: Turkey
facility: KSU Faculty of Medicine Research Hospital
Study officials:
References:
Clinical trial NCT03032900: Right Ventricular Dysfunction Incidence After Major Lung Resection
Official title: Right Ventricular Dysfunction Incidence After Major Lung Resection, a Prospective Study.
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Major Lung Resection
Right Ventricular Dysfunction
Keywords: Major lung resection
Right Ventricular Dysfunction
2D Strain
Lead sponsor: University Hospital, Montpellier
Sponsor class: OTHER
First posted: 2017-01-26
Enrollment: 110
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Major lung surgery

Brief summary: This study aims to describe incidence of right ventricular dysfunction after major lung resection with echocardiography criteria.

Detailed description: Few clinical trial studied the incidence of right ventricular dysfunction after major lung resection and time frame of occurrence.

In this prospective observational study the right ventricular function will be mesure with echocardiographic criteria. Echocardiographic exam will be standardised and be realised day before surgery (at the same time that inclusion), day 1, day 2 and day 3 after surgery.

In order to assess prognostic value of right dysfunction after lung resection, data as hospitalization stay, complications and survival will be collected at 6 months.

Cardiac cycles will be recorded and be analysed by a single observer blind to the clinical finding and other echocardiographic measurements.

Eligibility criteria: Inclusion Criteria:

* Written consent
* Patient older than 18 years
* Major lung surgery (pneumonectomy, lobectomy)

Exclusion Criteria:

* Pre-existing pulmonary arteria hypertension
* Post-operative surgical complication on day 1 to 3 (bleeding, revision surgery)
* Technical difficulty preventing adequate echocardiographic assessment
* Patient refusal

Primary outcomes:
measure: Right ventricular dysfunction
timeFrame: 5 days
Secondary outcomes:
measure: Risk factors
timeFrame: 5 days
measure: Time frame to right ventricular dysfunction
timeFrame: 5 days
measure: Assessment of 2D strain for right ventricular dysfunctio
timeFrame: 5 days
measure: Estimate impact of right ventricular dysfunction on patient prognosis.
timeFrame: 5 days
Other outcomes:
Locations:
city: Montpellier
country: France
facility: University Hospital
Study officials:
References:
Clinical trial NCT02067000: Patient Perception Questionnaire Validation
Official title: Validation of the Patient Perception Questionnaire
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Obstructive Sleep Apnea
Lead sponsor: Fisher and Paykel Healthcare
Sponsor class: INDUSTRY
First posted: 2014-02-20
Enrollment: 217
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: OSA patients

Brief summary: Validation of the patient perception questionnaire relating to CPAP use

Detailed description: This research is designed to validate a questionnaire which aims to predict patient adherence to CPAP, therefore enabling the healthcare provider to better target initiatives to improve adherence.

Eligibility criteria: Inclusion Criteria:

* Mild-severe OSA patients
* Over 18
* Naive to CPAP
* Fluent english

Exclusion Criteria:

* Comorbidities
* Other sleep disorders
* Inability to tolerate CPAP
* Shift worker

Primary outcomes:
measure: To Determine the Association of the Participants Baseline PPQ (Patient Perception Questionnaire) Responses to Predict Adherence to CPAP Treatment at 90 Days.
timeFrame: Baseline and 90 days
Secondary outcomes:
measure: Adherence to CPAP Treatment
timeFrame: 14 Days, 60 Days, 90 Days
measure: Reliability of Patient Perception Questionnaire
timeFrame: 14 days, 60 days, 90 days
Other outcomes:
Locations:
city: Saint Louis
country: United States
facility: Clayton Sleep Institute
state: Missouri
Study officials:
affiliation: Clayton Sleep Institute
name: Eric Powell
role: PRINCIPAL_INVESTIGATOR
References: